Marc Lippman, breast cancer expert, returns to Georgetown Lombardi

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Marc Lippman, a former director of Georgetown Lombardi Comprehensive Cancer Center, is returning as a professor in the departments of oncology and medicine at Georgetown University Medical Center, beginning July 15.

From 1988 to 2001, Lippman served as director of Georgetown Lombardi. During his tenure, he also served as chair of the Department of Oncology, and professor of oncology, medicine and pharmacology at Georgetown University Medical Center. Lippman joins Georgetown Lombardi as a member of the breast cancer program. He will also establish a laboratory and see patients with breast cancer.

Most recently, Lippman served as deputy director of Sylvester Comprehensive Cancer Center at the University of Miami as well as the Kathleen and Stanley Glaser Professor of Medicine at the University of Miami Miller School of Medicine.

Lippman is known for his work in the investigation and treatment of breast cancer. Before coming to Georgetown Lombard in 1988, he led the medical breast cancer section of the medicine branch at NCI, and was senior investigator from 1974 to 1988.

Lippman has been issued multiple patents for his work, including several related to the expression of growth factor receptors in tumor cells. He has published over 400 peer-reviewed articles and is editor-in-chief of Breast Cancer Research and Treatment.

Lippman’s wife, Nanette Bishopric, is a cardiologist and a professor of medicine at the University of Miami Miller School of Medicine, focusing on epigenetic mechanisms underlying heart failure and cancer. She plans to continue working with Lippman on several cancer projects, and will continue her clinical activities at MedStar Washington Hospital Center and MedStar Georgetown University Hospital.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login